LBL 043
Alternative Names: LBL-043Latest Information Update: 12 Jul 2024
At a glance
- Originator Nanjing Leads Biolabs
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 05 Apr 2024 Preclinical trials in Acute myeloid leukaemia in China (Parenteral)
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Acute myeloid leukaemia presented at the115th Annual Meeting of the American Association for Cancer Research (AACR-2024) (Leads Biolabs website, July 2024)